| Dokumendiregister | Majandus- ja Kommunikatsiooniministeerium |
| Viit | 10-2/1548-1 |
| Registreeritud | 28.04.2026 |
| Sünkroonitud | 29.04.2026 |
| Liik | Sissetulev kiri |
| Funktsioon | 10 Ettevõtlus ja innovatsioon |
| Sari | 10-2 Ettevõtete innovatsiooni, teadus- ja arendustegevuse kavandamise ja korraldamise kirjavahetus |
| Toimik | 10-2/2026 |
| Juurdepääsupiirang | Avalik |
| Juurdepääsupiirang | |
| Adressaat | Sillamäe Linnavalitsus |
| Saabumis/saatmisviis | Sillamäe Linnavalitsus |
| Vastutaja | Olari Püvi (Majandus- ja Kommunikatsiooniministeerium, Kantsleri valdkond, Majanduse ja innovatsiooni valdkond, Innovatsiooni ja tehnoloogia osakond) |
| Originaal | Ava uues aknas |
Kesk 27, 40231 Sillamäe [email protected] Tel +372 392 5700 www.sillamae.ee
Erkki Keldo
Majandus- ja tööstuminister
Pärt-Eo Rannap
Peadirektor
TAOTLUS
Lugupeetud härra majandus- ja tööstusminister,
Lugupeetud härra peadirektor,
Õiglase ülemineku mehhanismi eesmärk on toetada üleminekut kliimaneutraalsele
majandusele. Eestis on õiglase ülemineku keskmes Ida-Virumaa, kus suure
majandusliku ja keskkonnaalse mõjuga ning suure hõivatusega põlevkivitööstusest
loobumise tõttu tuleb leida lahendusi keskkonnaprobleemide lahendamisele,
tööstusharu asendava võimalikult suure lisandväärtusega tootmise ja ettevõtluse
arendamisele ning elukeskkonna parandamisele.
Selleks on õiglase ülemineku vahenditest ette nähtud võimalused toetada
innovaatilisi ettevõtlusprojekte. Meie hinnangul on põlevkivitööstuse asendamisel
oluline majanduse mitmekesistamine ning seejuures võimalikult suure
lisandväärtusega ja innovatiivsed projektid, mille rahastamiseks on keeruline leida
teisi toetusmeetmeid.
Sillamäe linn on arengukavas ette näinud vajaduse toetada GENECODE
biotehnoloogia ja ravimiarenduse projekti.
GENECODE AS on registreeritud aadressil Sillamäe Kesk 1b. GENECODE AS
innovatiivne ettevõte, mis on spetsialiseerunud biotehnoloogiliste lahenduste
Teie: Meie: 28.04.2026 a nr 12-3/749-1
SILLAMÄE LINNAVALITSUS
2
väljatöötamisele ja patenteerimisele. Ettevõttel on kõrgelt kvalifitseeritud meeskond
ning projekti jaoks vajalikud patendid.
GeneCode on Eesti ravimite arendamise ettevõte, mis keskendub ravimeetodite
väljatöötamisele neurodegeneratsiooni vastu võitlemiseks. Ettevõte on loonud
GDNF-i mimeetikumide platvormi, mis kasutab gliiarakkude päritoluga neurotroofse
faktori (GDNF) haigust modifitseerivaid omadusi ning rakendab neid
väikemolekulidele, millel on ravimilaadsed omadused. GeneCode on Euroopa juhtiva
biotehnoloogia uudisteportaali Labiotech poolt koostatud Eesti seitsme
silmapaistvama biotehnoloogiaettevõtte nimekirjas. GeneCode on silma paistnud
oma tootearendusprogrammiga, mis hõlmab ravimikandidaate selliste haiguste vastu
nagu amüotroofne lateraalskleroos (ALS), retiniit pigmentoosa (RP), põletikuline
soolehaigus (IBD) ja Parkinsoni tõbi (PD). Need ravimikandidaadid on loodud
haiguse progresseerumise aeglustamiseks, soodustades närvirakkude ellujäämist ja
funktsiooni.
Põlevkivikeemia ja eriti põlevkivi peenkeemia alase tootmise ja arendamise alase
potentsiaali äralangemisel on kohane ära kasutada sellekohaseid teadmisi ja
kogemusi suure tulevikupotentsiaaliga biotehnoloogia rahvusvahelise tipptasemega
arenduse ja tootmisega seotud investeeringuteks.
Ajalooliselt on Sillamäe linn loodud kohapealse keemiatehase tarvis, millele 1950-60
lisandus elanikkond, mis põhines ümbruskonna põlevkivitööstuse töötajatel, nii et
ligikaudu pool linna elanikest oli seotud otseselt põlevkivitööstusega. Ka täna kui
räägitakse Narva karjäärist või teistest põlevkiviettevõtetest, siis olenevalt
ettevõtetest töötab seal tegelikult oluline hulk Sillamäe elanikke (Narva karjääris
näiteks 95% töötajatest).
Leiame, et eeltoodud projekti oleks võimalik rahastada õiglase ülemineku
vahenditest, kui raha vabaneb nende projektide arvelt, mis erinevatel põhjustel ei
realiseeru.
Lugupidamisega /allkirjastatud digitaalselt/ Tõnis Kalberg linnapea lisad: projekti esildis ning projektide infomaterjalid
|
Tähelepanu!
Tegemist on välisvõrgust saabunud kirjaga. |
|
HOIATUS!
See e-kiri võib olla liba-, õngitsus- või pahaloomuline, kuna on saadetud asutusest, kus meiliserver on vigaselt seadistatud. |
|
Kesk 27, 40231 Sillamäe [email protected] Tel +372 392 5700 www.sillamae.ee
Erkki Keldo
Majandus- ja tööstuminister
Pärt-Eo Rannap
Peadirektor
TAOTLUS
Lugupeetud härra majandus- ja tööstusminister,
Lugupeetud härra peadirektor,
Õiglase ülemineku mehhanismi eesmärk on toetada üleminekut kliimaneutraalsele
majandusele. Eestis on õiglase ülemineku keskmes Ida-Virumaa, kus suure
majandusliku ja keskkonnaalse mõjuga ning suure hõivatusega põlevkivitööstusest
loobumise tõttu tuleb leida lahendusi keskkonnaprobleemide lahendamisele,
tööstusharu asendava võimalikult suure lisandväärtusega tootmise ja ettevõtluse
arendamisele ning elukeskkonna parandamisele.
Selleks on õiglase ülemineku vahenditest ette nähtud võimalused toetada
innovaatilisi ettevõtlusprojekte. Meie hinnangul on põlevkivitööstuse asendamisel
oluline majanduse mitmekesistamine ning seejuures võimalikult suure
lisandväärtusega ja innovatiivsed projektid, mille rahastamiseks on keeruline leida
teisi toetusmeetmeid.
Sillamäe linn on arengukavas ette näinud vajaduse toetada GENECODE
biotehnoloogia ja ravimiarenduse projekti.
GENECODE AS on registreeritud aadressil Sillamäe Kesk 1b. GENECODE AS
innovatiivne ettevõte, mis on spetsialiseerunud biotehnoloogiliste lahenduste
Teie: Meie: 28.04.2026 a nr 12-3/749-1
SILLAMÄE LINNAVALITSUS
2
väljatöötamisele ja patenteerimisele. Ettevõttel on kõrgelt kvalifitseeritud meeskond
ning projekti jaoks vajalikud patendid.
GeneCode on Eesti ravimite arendamise ettevõte, mis keskendub ravimeetodite
väljatöötamisele neurodegeneratsiooni vastu võitlemiseks. Ettevõte on loonud
GDNF-i mimeetikumide platvormi, mis kasutab gliiarakkude päritoluga neurotroofse
faktori (GDNF) haigust modifitseerivaid omadusi ning rakendab neid
väikemolekulidele, millel on ravimilaadsed omadused. GeneCode on Euroopa juhtiva
biotehnoloogia uudisteportaali Labiotech poolt koostatud Eesti seitsme
silmapaistvama biotehnoloogiaettevõtte nimekirjas. GeneCode on silma paistnud
oma tootearendusprogrammiga, mis hõlmab ravimikandidaate selliste haiguste vastu
nagu amüotroofne lateraalskleroos (ALS), retiniit pigmentoosa (RP), põletikuline
soolehaigus (IBD) ja Parkinsoni tõbi (PD). Need ravimikandidaadid on loodud
haiguse progresseerumise aeglustamiseks, soodustades närvirakkude ellujäämist ja
funktsiooni.
Põlevkivikeemia ja eriti põlevkivi peenkeemia alase tootmise ja arendamise alase
potentsiaali äralangemisel on kohane ära kasutada sellekohaseid teadmisi ja
kogemusi suure tulevikupotentsiaaliga biotehnoloogia rahvusvahelise tipptasemega
arenduse ja tootmisega seotud investeeringuteks.
Ajalooliselt on Sillamäe linn loodud kohapealse keemiatehase tarvis, millele 1950-60
lisandus elanikkond, mis põhines ümbruskonna põlevkivitööstuse töötajatel, nii et
ligikaudu pool linna elanikest oli seotud otseselt põlevkivitööstusega. Ka täna kui
räägitakse Narva karjäärist või teistest põlevkiviettevõtetest, siis olenevalt
ettevõtetest töötab seal tegelikult oluline hulk Sillamäe elanikke (Narva karjääris
näiteks 95% töötajatest).
Leiame, et eeltoodud projekti oleks võimalik rahastada õiglase ülemineku
vahenditest, kui raha vabaneb nende projektide arvelt, mis erinevatel põhjustel ei
realiseeru.
Lugupidamisega /allkirjastatud digitaalselt/ Tõnis Kalberg linnapea lisad: projekti esildis ning projektide infomaterjalid
GENECODE
Development of Disease-modifying Treatment for Neurodenerative Diseases
GDNF Mimetics Development History
RET, identied
as the GDNF
receptor
BT13 GDNF
receptor agonist
identication
In vivo target engagement
with BT13 (intracranial)
Improvement of motor
function in rat 6-OHDA with
BT44 (intracranial)
Start of lead optimization
with Serge Mignani
First cpds with same level of
ecacy as GDNF in vitro
First cpd, showing both brain
penetration after oral admin. and
neuroprotection in vitro
1. GDNF mimetic for Parkinson’s management. Mahato et al., 2020. 2. GDNF receptor RET agonist for PD. Renko et al., 2021.
1996 2009 Sep. 2022 Feb. 20232021 Jan. 2022
Neuroprotection show in human
DA neurons (EAR586, EAR685)
EAR993 showing improved metabolic stability and brain penetra-
tion (MDCK)
3 new patents led
IND enabling Phase 1a / Phase 2aEAR911 showing higher neuroprotection
than GDNF in human DA neurons
IND/CTA- enabling studies
March 2023 June 2023 Jan. 2024 March 2025July 2023 Aug. 2023 March 2026 March 2027
Neurotrophic Factors and Parkinson’s Disease
3
Growth factors do not only protect but also restore degenerating neurons, promote arborization and sprouting of their neurites, and enhance their functional activity
Patients with Parkinson's disease:
• 1% of people over the age of 65 are developing Parkinson's disease
• 10 million patients worldwide have been diagnosed with PD, with this number expected to double by 2040
• Economic Burden (US 2017) = $51B
• Motor symptoms are partially addressed but no disease-modifying drug exists to protect or restore dopamine neurons
• No treatment for non- motor symptoms
Neurotrophic factors are an attractive target for supportive and neuro- restorative therapeutic approaches
• Progressive neurodegenerative disorder
• Degeneration and loss of dopamine neurons is associated with motor and non-motor symptoms of PD
Sidorova and Saarma TIPS, 2020; Mahato AK and Sidorova YA. Cell Tissue Res. 2020
Neurotrophic Effects of GDNF Revealed in Patients with PD
Core Treatment Details • 21 per group, with mid-stage PD, all receiving four catheters and port (new design)
• Infusion every 4 weeks for 40 weeks (GDNF-240 ug or vehicle) then all patients are rolled over into an open-label all active (40 weeks)
Efficacy Summary
• Primary efficacy outcome not statistically significant (UPDRSIII in OFF time)
• Improvements in good “ON time” over baseline (will be the primary endpoint for future trials)
• Biological effect demonstrated by PET Imaging. Expert: Prof. Jon Stoessl
4
Finding Small Molecule with same MOA as GDNF
5
Targeting GDNF receptors with small molecules
GDNF family ligands GDNF and NRTN activate GFRα-RET receptors promoting survival and regenerating axons of dopamine neurons in
neurotoxin animal models of PD
EAR911 activates GDNF signalling pathways via RET receptor
6
LUCIFERASE ASSAY DIRECT RET PHOSPHORYLATION ASSSAY
EAR911- Mouse PO pharmakokinetics
7
Formulation: 10 % DMSO, 10 % Solutol H15, 40% PEG 200, 40 % 0.01% Tween 80 in 10 mM Tris buffer pH8
EAR911 protects both wild-type and α-synuclein mutated human dopamine neurons from neurotoxin-induced cell death
8
Wild-type Human Dopamine Neurons α-synuclein A53T-Mutated Human Dopamine Neurons
EAR911 penetrates blood-brain barrier and increases dopamine release
9
Systemic delivery of EAR911 improves motor coordination and motor learning in rotarod test in the MPTP-Probenecid mouse model of Parkinson’s disease
10
EAR911 rescues gastrointestinal tract dysfunction in the MPTP-Probenecid mouse model of Parkinson’s disease
11
From biological concept to small-molecule drug
12
GDNF
EC50 = 5 nM
Efficacy= 100%
Active in patients
Intraputaminal administration
BT13
EC50 = 13000 nM
Efficacy= 10%
Active in rodents models of Parkinsons’s disease
Intraputaminal administration
EAR911
EC50 = 5 nM (Neuroprotection)
Efficacy= 100%
Active in patients
Neuroprotection in human dopamine
neurons, penetrates BBB and stimulates
dopamine release, improves both motor and
non-motor symptoms in MPTP model of PD
Take-Home Message
13
• EAR911 penetrates BBB and stimulates dopamine release
• EAR protects and regenerates human iPSC-derived wild-type and α-synuclein mutated dopamine neurons
• EAR911 in mouse model of Parkinson’s disease improves global motor behavior of mice
• Most importantly, systemically delivered EAR911 dramatically reduced constipation and normalized the function of gastrointestinal tract (GIT)
• Currently, we are analyzing the brain tissues from MPTP study by immunohistochemistry
Possible Targets of GDNF Mimetics
• Successfully continuing PD development
means that GeneCode has a wide range of
potential follow-up activities based on the
GDNF Mimetics platform development.
• Our preliminary studies indicate that the 3
most promising indications are:
Amyotrophic Lateral Sclerosis (ALS),
Retinitis Pigmentosa (RP), and
Inflammatory Bowel Disease (IBD).
• As a proof of concept, we have started
studying GDNF mimetics both in vitro and
in vivo model of ALS, RP and IBD
14
Neurotrophic factors and Amyotrophic lateral sclerosis ( ALS )
15
• ALS is fatal neurodegenerative disease affecting both upper and lower motor neurons
• The progressive loss of motor neurons causes rapid loss of motor control, leading to paralysis and death within 3-5 years of symptom onset
• Glial cell line-derived neurotrophic factor (GDNF) has the potential to support the survival and maintenance of motor neurons with 100 times more efficacious than other trophic factors
• A recent Phase I/II safety study was conducted by transplanting human progenitor cells (hNPCs) engineered to produce and secrete GDNF unilaterally to the lumbar spinal cord. In this safety trial, the primary endpoint of safety was met, and the results from postmortem tissues grafted cells survived and produced GDNF
• The second clinical trial is underway to evaluate the cortical delivery of hNPCs-GDNF
.
Neurotrophic factors and Inflammatory bowel disease (IBD)
16
• IBD is a term for two conditions Crohn's disease (CD) and ulcerative colitis (UC) and is characterized by chronic inflammatory process of patient’s gut
• Disruption of intestinal epithelium layer is a semi permeable physical barrier might play role in the development and progression of IBD
• GDNF and its receptors are significantly expressed in intestine and play important role regulating epithelia tight junction in the intestinal epithelial barrier (IEB) and protect intestinal cell invasion from bacterial infection
• GDNF also acts as anti-inflammatory agent in murine models of colitis
• Recent finding indicate that GDNF was significantly reduced in IBD patients with CD and UC, indicating disease-relevant contribution to the development of IEB dysfunction
• Our recent finding shows that GDNF mimetics recues gastrointestinal dysfunction which indicates that GDNF mimetics can be drug for IBD
Patients with IBD:
• About 4 million females and 3 million males are living with IBD worldwide and cases is on rise
• The prevalence of IBD was reported to range from 252 to 439 cases per 100 000 population in the USA.
Neurotrophic factors and Retinitis pigmentosa (RP)
17
HEALTHY RETINA RETINITIS PIGMENTOSA
Patients with Retinitis Pigmentosa:
• The worldwide prevalence of retinitis pigmentosa is about 1 in 4000 for a total of more than 1 million affected individuals.
• Currently, there are no treatment available to stop the disease progression and restore the vision
• As a proof of concept, we are studying GDNF mimetic in both in vitro and in vivo models of RP
• RP is a group of inherited disorders characterized by the progressive dysfunction of predominantly rod followed by cone photoreceptor cells
• GDNF receptors are predominantly expressed in retinal ganglionic cells as well as in Müller cells of the retina
• Both in vitro as well as in vivo studies show that GDNF promotes the survival of photoreceptor and ganglionic cells after injury
• Recently, subretinal injection hNPCs-GDNF has shown significant neuroprotection and enables the extended survival of photoreceptor cells in transplanted animal eyes
• Phase I/IIa clinical trial of transplanting hNPCs- GDNF into the subretinal space of RP patients is ongoing
Development Overview An Estonia-based biotech company focused on developing small molecule GDNF mimetics with the potential for disease-modifying treatments for nervous system disorders
18
Drug Development Launch 2007 HQ in Tallinn, Estonia Team of 20+ EUR 14.2m Funding to date
Genecode’s lead compounds for PD will enter the IND phase in 2024
Management Team
Paavo Pilv, EMBA CEO, Partner
Prof. Dr. Mart Saarma CSO, Partner
Prof. Dr. Tarmo Tamm Lead Scientist
EUR 14.3m Equity investment commitment from EIC
The annual listing of 10 companies in the EU that are at the forefront of
providing Drug Discovery and Development solutions, impacting the
industry in the region
Key Partners:
Patents x3 x1
GeneCode is developing novel small molecule GDNF mimetics with the potential for disease-modifying treatments for nervous system disorders
Pre-clinical Trials IND Phase Clinical Trials finalized in 2024 2024-2025 2025+
Paavo Pilv, EMBA, CEO of GeneCode, JMC member of Kevad Bio
Yves Ribeill, PhD, Partner, Entrepreneur-In-Residence, Co-founder of Argobio Studio, JMC member of Kevad Bio
Delphine Charvin, PhD, Operating Partner at Argobio Studio, JMC member of Kevad Bio
Mélanie Rouillier, MSc, PMP, Scientific Project Manager at Argobio Studio
Serge Mignani, PhD, Consultant in Medicinal Chemistry for Argobio Studio
Prof. Dr. Tarmo Tamm, University of Tartu, lead scientist of GeneCode
Prof. Dr. Mart Saarma, Research Director and Professor at the Institute of Biotechnology, University of Helsinki, Sr Partner of GeneCode, CSO, JMC member of Kevad Bio
Arun Mahato, PhD, Institute of Biotechnology, University of Helsinki, lead scientist of GeneCode
Co re
T ea
m Dr. Mehis Pilv, The Company Founder
Discovery Lead Op Preclinical IND Ph I Ph II Ph III
KB-001 (GFRɑ1-RET)
Neuro-protection and restoration in PD
KB-xxx (GFRɑ1-RET)
3 new indications: ALS, RP, IBD
Other
Weight loss
Addiction diseases
Timeline Building a Valuable Pipeline
Today Ahead of Series A
20
Market analyses Building a Valuable Pipeline
21
Indication Patients Compound annual growth rate (CAGR)
Market value Future market value
PD Over 10 million worldwide
14,5% Global market value 2022 $3.4 billion
$7,1 billion by 2029
ALS 4-6 cases per 100,000 individuals
13,9% $282 million in 2019 within the 8 MM
Exceed $1.04 billion by 2029
RP Affects approximately 1 in every 3,000
7,3% Global market value 2021 $11.57 billion
$20.33 billion by 2029
IBD 6-8 million individuals worldwide
5,7% Global market value 2022 $25.18 billion
$37 billion by 2029
ARE WE TALKING ABOUT A POTENTIAL NEW UNICORN?
200
400
600
800
1 000
1 200
Discovery Preclinical Phase 1 Phase 2 Phase 3
Upfront payment Milestone payment Total deal value
Parkinson's Disease - Deal Comparables: Segmented by Stage
of Development
Existing drugs are generic and have very similar treatment
paths. The GeneCode drug is the first one that restores the
neurons affected by PD.
The strategy is to secure a strategic corporate partnership with an
industry-leading pharmaceutical company. The core takeaway
from the deal/transaction comparable analysis shown here is that
there are multiple key time points where GeneCode can expect
to secure a corporate partnership (i.e., preclinical, Phase 1, 2,
3).
$M
The main drive behind these very lucrative financial deals is innovative PD drug treatments offering ‘disease-modifying’ abilities. GeneCode is developing novel PD therapies that also have this important attribute of disease-modifying potential.
Contact
Paavo Pilv CEO
E-mail: [email protected] Mobile: +372 50 20 111GENECODE
Paavo Pilv CEO
E-mail: [email protected] Mobile: +372 50 20 111 [email protected] [email protected]
WORLD TRADE CENTRE®
TALLINN
WTC Tallinn Ltd planned renovation
WTC TALLINN is located in the city centre, between the Old Town, the airport and the port, which serves 12-13 million passengers per year.
WTC Tallinn is the largest privately owned and privately operated office spaces offering company in the Nordic-Baltic region.
WTC Tallinn recently celebrated its 30th year of successful operations.
Starting date of the WTC Tallinn Development Pro- ject is known very precicely - 15th of April 1994. That day formed for that pur- pose and leaded by Dr. Mehis Pilv In- vestment Company RET Development Group LTD bought on the public auc- tion the pancropthed Tallinn Radielectron- ic Plant (RET) big Industrial Quarter in the Tallinn City Centre.
Taking care of the highly attractive location in the Tallinn City Centre, his buildings, proper- ties and the infrastructure, this big Industrial Quarter was decided to convert to the big In- ternational Business Quarter and to apply for it the brand name “World Trade Center Tallinn“. One of the most prominent Estonian Architects Mr. Raine Karp made the shown here the first arhitectual version of this planned to be devel- oped Tallinn Big International Business Quarter and the Application Documents for getting the Tallinn World Trade Center brand name were sent to the World Trade Centers Association (WTCA) HQ in New York.
The RET Development Group WTC Tallinn Brand name Application was in WTCA HQ well accepted and the prepearing of the cor- responding WTCA Membership decicion documentation was delecated to the Chair- man of the Industrializing Nations Committee of the WTCA, Mr. K.H. Wu of WTC Taipei. In connection of defining the various local, related to the Applicant questions, Tallinn was visited by the appointed by the WTCA repre- sentatives - many times by the Regional Coor-
dinator for Central and Eastern Europe of the Industrializ- ing Nations Com- mittee of the WTCA Mr. Guenter Ehring, Director of the WTC RUHR VALLEY.
With prepearing the WTC Tallinn WTCA Membership deci- sion worked also Mr. Matthew Kleink-
necht from the WTCA HQ and among others also Vice President and Secretary General of the WTCA Mr. Tom Kearney. The WTC Tallinn WTCA Membership Application was Supported by the WTCA Board Meetings, by 1995 WTCA Spring Meeting in Mexico and WTCA General Assembly in Beijing and the WTC Trade mark was granted to the WTC Tallinn on April 24, 1995.
Ambitious and innovative use by companys management the various competive advan- tages of this Big Private Tallinn WTC Quarter had made the WTC Tallinn Project from the very beginning selfsufficient and ecomically very profitable during all of the more then 30 years of its succesful operations.
Starting in 2025 the new full Reconstruction of the WTC Tallinn Business Quarter can also be characterized by using of many very ambitious and innovative newest technologies, from outstanding and flexible modern architectual solutions to the AI controlled best possible in- door climate for users. The buildings with best possible energy performance are engineered to be zero emission buildings (ZEB) and they will harvest renewable heating and cooling energy with geothermal heat pump with effec- tive thermal storage in the ground.
Forming of THE WTC TALLINN LTD in 15.04.1994
2
Crucial for occupants comfort air condition-
ing and ventilation systems are silent oper- ation, low velocities and high level of ther- mal comfort and Indoor Air Quality (IAQ ), for that will be used a low-pressure ventilation ductwork of combined air conditioning and heat recovery demand-controlled ventilation system.
Very important are also many unic flexible architectual-constructoral technological solu- tions, which will be also described in more.
DETAILS
All those newest ambitious arhitectural - constructoral - technological solutions with using newest high efficiency AI software will be described more precicely in the next parts of this manual. Also is very important to un- derline, that thanks to very high efficiency of the technological solutions of many WTC Tal- linn Quarter infrastructure systems, some ser- vices can be additionally to the clients of the own WTC Quarter be very profitable deliv- ered also to the neighboring properties - for example central heat and cooling, electrical energy, parking places, connections to public transport et cetera.Tallinn International Electronics
and Trade Center
Architect Raine Karp sketch project from 1994
Borders the harbor area
3
DR. MEHIS PILV has a Ph.D. in Applied Computer Sciences, more than 20 publications on radio-electronics, applied cybernetics and international entrepreneur- ship and more than 10 inventions and patents.
Dr. Pilv is the founder of WTC Tallinn Ltd. He is also the founder GENE- CODE and is a significant investor and business developer.
He is a private owner of the World Trade Center, Tallinn and also has inter- ests in many significant real estate projects.
https://genecode.com/team/mehis-pilv/
The renewable geothermal energy from the WTC Tallinn territory is provided by MAAKÜTE LTD (Geothermal heat energy).
The construction of the WTC Tallinn quarter is being provided by Estonia’s leading construction company MERKO.
WTC Tallinn development team
WTC Tallinn’s ambitious reconstruction project is ensured by the use of top professionals from various fields.
PROF. DR. ANDRES ALVER has taught at the Estonian Academy of Arts (formerly ERKI) since 1985. Since 2006, he has been a full professor. He has worked as a visiting pro- fessor at the College of Architecture of the Virginia Polytechnic Institute (Alexandria, VA) and at the Faculty of Architecture of the private university RISEBA in Riga, and has been a visiting critic at the Department of Archi- tecture of Umea University (Sweden) and the School of Design of Harvard University (Cambridge, MA). www.ata.ee
The globally ambitious architectural solution has been developed by Professor Andres Alver, who is the developer of the architectural solu- tions for many of the new developments in Tallinn. Such as the Roter- mann Center, Krulli Quarter, Smuuli tee Quarter, and so on.
4
PROF. DR. JAREK KURNITSKI is Professor at Tallinn University of Technology, Estonia, and at Aalto Uni- versity, Finland. He is internationally renowned for preparation of techni- cal definitions for nearly zero energy buildings through many activities in REHVA and European standardisation. www.etis.ee/CV/Jarek_Kurnitski/
The ambitious architecture is complemented by one of Estonia’s leading design offices, Disainikorp, with its innovative design solutions.
MA. KAREL KORP Karel Korp is an Estonian designer, illustrator, book designer and painter.
Graduated from Tallinn University with a degree in art education and drawing. In 1997, he founded the advertising and design agency Disaini- korp, which is one of the oldest operating design agencies in Estonia.
He has collaborated with the Bank of Estonia, the Financial Supervision Authority, the Chancellor of Justice, the Employers’ Confederation, the Chamber of Commerce and Industry, the Estonian Cooperation Council, the World Trade Center Tallinn and many other institutions and compa- nies. He has created trademarks and corporate graphics for international- ly operating companies.
He has participated in dozens of exhibitions with his illustrations and paintings both in Estonia and elsewhere in the world.
From 2016 to the present, he has been the chairman of the Estonian Graphic Designers’ Association and one of the owners of the illustration gallery TINT.
www.disainikorp.ee
The most important innovative solution for the reconstructed WTC is to power the new quarter with 100% renewable energy all year round.
The corresponding direction has been developed by Professor Jarek Kurnitski of Tallinn University of Technology and Professor Robert Kitt, Head of Utilitas.
5
Zero Emission Building and optimal Indoor Environmental
Quality targets in
WTC Tallinn In addition to the striking and unique
architectural design, the building’s CO2 footprint and its unique solution based on 100% renewable
geothermal and solar energy should also be noted.
This is described in more detail on the following page.
6
Certified to the highest level of LEED/ BREEAM/WELL should not only demonstrate modern architecture but also to offer best possible indoor climate for users. An opti- mal Indoor Environmental Quality (IEQ ) is of- ten overlooked in value engineering, but it deserves efforts for better user satisfaction, wellbeing and productivity. In WTCT this goes hand in hand with best possible energy per- formance as these buildings aim to be zero emission buildings (ZEB) and beyond before an official definition of ZEB even exists. There are the following three innovative elements to achieve ZEB and optimal IEQ targets in WTCT.
1.
WTCT buildings located in city centre will harvest renewable energy with semi deep boreholes and photovoltaic on-site electric- ity generation. Because of limited size of the building site a common borehole in Estonian soil conditions of 50 m will be replaced with much deeper one. Ongoing experimental drill- ing aims to reach about 600 m with three test boreholes which then will enable to conduct a thermal response test to provide design data for the entire borehole field. It is expected that boreholes with a geothermal heat pump will supply most of the heating and cooling of buildings and enable effective thermal storage in the ground. The rest of heating and cooling energy will be covered with effective district heating and cooling.
2.
To reduce heating and cooling loads, highly performing façade would be needed. As lo- cated in cold climate, facades with four pane glazing units are studied instead of common
triple glazing. Four pane windows with clear low-emission glazing offer superior thermal in- sulation and solar protection at the same time while visible light transmittance can reach 60% that is well enough for facades having high window to wall ratios because of sea views and other architectural reasons. The drawback of four panel glazing are higher weight and a challenge for profile systems to have a space for more than 70 mm thick glazing units. De- pending on energy prices such solution can be cost effective in the long run and WTCT wants to be a forerunner focusing to life cycle cost instead of investment cost.
3.
Air conditioning and ventilation systems are crucial for occupant’s comfort. WTCT pre- fers silent operation, low velocities and sys- tems operating on demand to provide high level of thermal comfort and Indoor Air Qual- ity (IAQ ). A low-pressure ventilation ductwork of combined air conditioning and heat recov- ery demand-controlled ventilation system will be used. This system sized for terminal unit pressure drop has lower velocities and static pressure in the ductwork than usually making it flexible and robust for demand control op- eration even with simple on-off type of damp- ers. WTCT aims to design one of the first air conditioning and ventilation systems in Esto- nia having IAQ regulation and monitoring that is one important feature of future ZEBs. Such design makes IEQ visible for users and bene- fits from utilising passive features but will take more space because of larger ducts. However, careful architectural design and high ceilings in WTCT turn this to be a reasonable solution maximising both energy and IEQ performance.
WTC Tallinn Business Quarter with Zero Emission and optimal Indoor Environment office and living buildings
7
Parda T1 (internal street) 2024 m2
In the quarter, which has a total of 20,000 m2 of plot area and 100,000 m2 of building area, all buildings are accessible by car from various directions.
The street is also wide enough to allow access to the first- floor commercial buildings by commercial vehicle.
Public transport options are located in the immediate vicin- ity of the quarter, which directly connect the port and the airport.
8
NARVA ROAD
Ahtri 8 Ahtri 12
Parda 9
Parda 5
Parda 4 Jõe 3
Jõe 5
Narva 11
Jõe 5A apartment building
Jõe 7 apartment building
Jõe 9
Parda 8
Parda 10
Parda 12
Parda 6
Parda T1 (internal street) 2 024 m2 • 100% WTC
AHTRI STREET
Narva 9
JÕ E STR
EET
◀ ROTERMANN QUARTER
REIDI ROAD ▶
Parda 7
Parda 3
◀ PORTO FRANCO
Parda T1 (internal street) 2024 m2
9
Parda T1 (internal street)
10
11
12
13
Tallinn’s passenger port is around ½ a kilometer away, the city’s main rail- way station is around 3 kilometers away, and Tallinn Airport is around 4 kilometers away.
WTC Tallinn quarter
WTC Tallinn quarter compared to the neighboring Rotermann business district
14
Rotermann quarter
View from Tallinn Town Hall SquareTown Hall Square in the Old Town is around 2 kilometers away.
Starting from this summer, you will be able to take the tram from the harbour directly to the main entrance of the WTC.
15
Parda 9, Ahtri 8/12, Jõe 9 towers reconstructed buildings Upper floor general plan. Gross floor area 3307 m2
View of the projecting part of the apartment
16
132.3 m2
118.4 m2
17
Parda 9, Ahtri 8/12, Jõe 9 towers reconstructed buildings Upper floor general plan. Gross floor area 3307 m2
View of the projecting part of the apartment
18
88.9 m2
82.3 m2
Apartments on the upper floors of Ahtri 8-12
19
1:1 tenant on the floor 2:3 tenant on the floor
931 m2
209 m2 99 m2
107 m2
167 m2
Parda street 3, 5, 7 towers According to the detailed plan, the construction of both offices and living spaces is secured.
20
The three towers above at Parda 3, 5 and 7 are multifunctional buildings with plan- ning permits for both office and residen- tial space. A sufficient number of parking spaces has been provided for both. The towers are planned to be 11-storey build- ings with a height of 38.5 m.
The three described office buildings are designed to conform to the class A stand- ard, which means zero-energy buildings in terms of energy consumption. The lo- cation of the office buildings in the WTC Tallinn quarter provides a significant com- petitive edge.
Technical data of the Parda street 3, 5, 7 three properties:
• Area available for construction: 2 294m2
• No. of floors: 11 • Gross area: 19 077m2
• Net area: 17 309m2
• Parking spaces: 222
21
22
WTC Tallinn Ltd Ahtri 8, 10151 Tallinn, Estonia Phone: +372 626 1001 E-mail: [email protected] • www.wtc.ee
Collaboration and investment proposals: Mehis Pilv, member of the board of WTC Tallinn Phone: +372 50 31 801 E-mail: [email protected] [email protected]
The figure below shows a multifunctional building extending onto the pedestrianised Ahtri Street, the main part of which is an ex- clusive projecting section resting on a braid- ed pipe. Here, too, there will be both office and residential spaces with sufficient parking.
The building was designed to be an energy efficiency class A structure, i.e. a nearly zero energy building with the best available ener- gy efficiency and renewable energy technol- ogy.
23
Area of buildings owned by WTC Quarter
68 313 m2
Area of the properties owned by WTC 12 775 m2
Area of buildings operated by WTC Quarter
30 965 m2
Area of the properties operated by WTC 6 568 m2
Area of the buildings in the quarter
TOTAL: 99 278 m2 or approx. 1 million square feet
Total area of the properties 19 343 m2
NARVA ROAD One of Tallinn’s busiest roads
Ahtri 8 Ahtri 12
Ahtri 8/12 - 23 810 m2 (Current enclosed net area 11 432 m2, according to the zoning plan 23 810 m2, WTC part 93.43%)
Parda 9
Pa rd
a 3,
5 , 7
Parda 4 Jõe 3
Jõe 5
Narva 11
Jõe 5A apartment building
Jõe 7 apartment building
Jõe 9
Parda 8
Parda 10
Parda 12
Parda 6
Jõe 9 - 2 925 m2
100% WTC
Parda 4 3 745 m2
100% WTC
Parda 3, 5, 7 19 020 m2
100% WTC Current enclosed net area 2 617 m2, according to the zoning plan 19 020 m2
Parda 9 - 14 950 m2
Current enclosed net area 9 960 m2, according to the zoning plan 14 950 m2
Parda T1 (internal street) 2 024 m2 • 100% WTC
AHTRI STR.
Narva 9
Additional access to the WTC Quarter
JÕ E STR
.
Additional connection to the WTC Quarter
Building managed by WTC
Property area 2 172 m2
Parda 7 property area 908 m2
Parda 5 property area 1 037 m2
Parda 3 property area 931 m2
Property area 2 977 m2
Property area 710 m2
Property area 740 m2
Property area
295 m2
Property area
240 m2
Property area
905 m2
Current enclosed net area 2 831 m2
Property area
539 m2
Current enclosed net area 1 946 m2
Property area
1 276 m2
Current enclosed net area 3863 m2
Property area 1 406 m2
Current enclosed net area 8 633 m2
Property area 543 m2
Current enclosed net area 4 050 m2
Property area
1 739 m2
Current enclosed net area 7 869 m2ROTERMANN
QUARTER
REIDI ROAD
Current enclosed net area 720 m2
Current enclosed net area 1 999 m2
Property area 901 m2
Current enclosed net area 881 m2
PORTO FRANCO
THE TALLINN WTC QUARTER designed by Professor Andres Alver according to the zoning plan from 2010, with updates starting from 2025
DELFI QUARTER
Parda T1 (internal street)
2 024 m2 • 100% WTC
GENECODE
Development of Disease-modifying Treatment for Neurodenerative Diseases
GDNF Mimetics Development History
RET, identied
as the GDNF
receptor
BT13 GDNF
receptor agonist
identication
In vivo target engagement
with BT13 (intracranial)
Improvement of motor
function in rat 6-OHDA with
BT44 (intracranial)
Start of lead optimization
with Serge Mignani
First cpds with same level of
ecacy as GDNF in vitro
First cpd, showing both brain
penetration after oral admin. and
neuroprotection in vitro
1. GDNF mimetic for Parkinson’s management. Mahato et al., 2020. 2. GDNF receptor RET agonist for PD. Renko et al., 2021.
1996 2009 Sep. 2022 Feb. 20232021 Jan. 2022
Neuroprotection show in human
DA neurons (EAR586, EAR685)
EAR993 showing improved metabolic stability and brain penetra-
tion (MDCK)
3 new patents led
IND enabling Phase 1a / Phase 2aEAR911 showing higher neuroprotection
than GDNF in human DA neurons
IND/CTA- enabling studies
March 2023 June 2023 Jan. 2024 March 2025July 2023 Aug. 2023 March 2026 March 2027
Neurotrophic Factors and Parkinson’s Disease
3
Growth factors do not only protect but also restore degenerating neurons, promote arborization and sprouting of their neurites, and enhance their functional activity
Patients with Parkinson's disease:
• 1% of people over the age of 65 are developing Parkinson's disease
• 10 million patients worldwide have been diagnosed with PD, with this number expected to double by 2040
• Economic Burden (US 2017) = $51B
• Motor symptoms are partially addressed but no disease-modifying drug exists to protect or restore dopamine neurons
• No treatment for non- motor symptoms
Neurotrophic factors are an attractive target for supportive and neuro- restorative therapeutic approaches
• Progressive neurodegenerative disorder
• Degeneration and loss of dopamine neurons is associated with motor and non-motor symptoms of PD
Sidorova and Saarma TIPS, 2020; Mahato AK and Sidorova YA. Cell Tissue Res. 2020
Neurotrophic Effects of GDNF Revealed in Patients with PD
Core Treatment Details • 21 per group, with mid-stage PD, all receiving four catheters and port (new design)
• Infusion every 4 weeks for 40 weeks (GDNF-240 ug or vehicle) then all patients are rolled over into an open-label all active (40 weeks)
Efficacy Summary
• Primary efficacy outcome not statistically significant (UPDRSIII in OFF time)
• Improvements in good “ON time” over baseline (will be the primary endpoint for future trials)
• Biological effect demonstrated by PET Imaging. Expert: Prof. Jon Stoessl
4
Finding Small Molecule with same MOA as GDNF
5
Targeting GDNF receptors with small molecules
GDNF family ligands GDNF and NRTN activate GFRα-RET receptors promoting survival and regenerating axons of dopamine neurons in
neurotoxin animal models of PD
EAR911 activates GDNF signalling pathways via RET receptor
6
LUCIFERASE ASSAY DIRECT RET PHOSPHORYLATION ASSSAY
EAR911- Mouse PO pharmakokinetics
7
Formulation: 10 % DMSO, 10 % Solutol H15, 40% PEG 200, 40 % 0.01% Tween 80 in 10 mM Tris buffer pH8
EAR911 protects both wild-type and α-synuclein mutated human dopamine neurons from neurotoxin-induced cell death
8
Wild-type Human Dopamine Neurons α-synuclein A53T-Mutated Human Dopamine Neurons
EAR911 penetrates blood-brain barrier and increases dopamine release
9
Systemic delivery of EAR911 improves motor coordination and motor learning in rotarod test in the MPTP-Probenecid mouse model of Parkinson’s disease
10
EAR911 rescues gastrointestinal tract dysfunction in the MPTP-Probenecid mouse model of Parkinson’s disease
11
From biological concept to small-molecule drug
12
GDNF
EC50 = 5 nM
Efficacy= 100%
Active in patients
Intraputaminal administration
BT13
EC50 = 13000 nM
Efficacy= 10%
Active in rodents models of Parkinsons’s disease
Intraputaminal administration
EAR911
EC50 = 5 nM (Neuroprotection)
Efficacy= 100%
Active in patients
Neuroprotection in human dopamine
neurons, penetrates BBB and stimulates
dopamine release, improves both motor and
non-motor symptoms in MPTP model of PD
Take-Home Message
13
• EAR911 penetrates BBB and stimulates dopamine release
• EAR protects and regenerates human iPSC-derived wild-type and α-synuclein mutated dopamine neurons
• EAR911 in mouse model of Parkinson’s disease improves global motor behavior of mice
• Most importantly, systemically delivered EAR911 dramatically reduced constipation and normalized the function of gastrointestinal tract (GIT)
• Currently, we are analyzing the brain tissues from MPTP study by immunohistochemistry
Possible Targets of GDNF Mimetics
• Successfully continuing PD development
means that GeneCode has a wide range of
potential follow-up activities based on the
GDNF Mimetics platform development.
• Our preliminary studies indicate that the 3
most promising indications are:
Amyotrophic Lateral Sclerosis (ALS),
Retinitis Pigmentosa (RP), and
Inflammatory Bowel Disease (IBD).
• As a proof of concept, we have started
studying GDNF mimetics both in vitro and
in vivo model of ALS, RP and IBD
14
Neurotrophic factors and Amyotrophic lateral sclerosis ( ALS )
15
• ALS is fatal neurodegenerative disease affecting both upper and lower motor neurons
• The progressive loss of motor neurons causes rapid loss of motor control, leading to paralysis and death within 3-5 years of symptom onset
• Glial cell line-derived neurotrophic factor (GDNF) has the potential to support the survival and maintenance of motor neurons with 100 times more efficacious than other trophic factors
• A recent Phase I/II safety study was conducted by transplanting human progenitor cells (hNPCs) engineered to produce and secrete GDNF unilaterally to the lumbar spinal cord. In this safety trial, the primary endpoint of safety was met, and the results from postmortem tissues grafted cells survived and produced GDNF
• The second clinical trial is underway to evaluate the cortical delivery of hNPCs-GDNF
.
Neurotrophic factors and Inflammatory bowel disease (IBD)
16
• IBD is a term for two conditions Crohn's disease (CD) and ulcerative colitis (UC) and is characterized by chronic inflammatory process of patient’s gut
• Disruption of intestinal epithelium layer is a semi permeable physical barrier might play role in the development and progression of IBD
• GDNF and its receptors are significantly expressed in intestine and play important role regulating epithelia tight junction in the intestinal epithelial barrier (IEB) and protect intestinal cell invasion from bacterial infection
• GDNF also acts as anti-inflammatory agent in murine models of colitis
• Recent finding indicate that GDNF was significantly reduced in IBD patients with CD and UC, indicating disease-relevant contribution to the development of IEB dysfunction
• Our recent finding shows that GDNF mimetics recues gastrointestinal dysfunction which indicates that GDNF mimetics can be drug for IBD
Patients with IBD:
• About 4 million females and 3 million males are living with IBD worldwide and cases is on rise
• The prevalence of IBD was reported to range from 252 to 439 cases per 100 000 population in the USA.
Neurotrophic factors and Retinitis pigmentosa (RP)
17
HEALTHY RETINA RETINITIS PIGMENTOSA
Patients with Retinitis Pigmentosa:
• The worldwide prevalence of retinitis pigmentosa is about 1 in 4000 for a total of more than 1 million affected individuals.
• Currently, there are no treatment available to stop the disease progression and restore the vision
• As a proof of concept, we are studying GDNF mimetic in both in vitro and in vivo models of RP
• RP is a group of inherited disorders characterized by the progressive dysfunction of predominantly rod followed by cone photoreceptor cells
• GDNF receptors are predominantly expressed in retinal ganglionic cells as well as in Müller cells of the retina
• Both in vitro as well as in vivo studies show that GDNF promotes the survival of photoreceptor and ganglionic cells after injury
• Recently, subretinal injection hNPCs-GDNF has shown significant neuroprotection and enables the extended survival of photoreceptor cells in transplanted animal eyes
• Phase I/IIa clinical trial of transplanting hNPCs- GDNF into the subretinal space of RP patients is ongoing
Development Overview An Estonia-based biotech company focused on developing small molecule GDNF mimetics with the potential for disease-modifying treatments for nervous system disorders
18
Drug Development Launch 2007 HQ in Tallinn, Estonia Team of 20+ EUR 14.2m Funding to date
Genecode’s lead compounds for PD will enter the IND phase in 2024
Management Team
Paavo Pilv, EMBA CEO, Partner
Prof. Dr. Mart Saarma CSO, Partner
Prof. Dr. Tarmo Tamm Lead Scientist
EUR 14.3m Equity investment commitment from EIC
The annual listing of 10 companies in the EU that are at the forefront of
providing Drug Discovery and Development solutions, impacting the
industry in the region
Key Partners:
Patents x3 x1
GeneCode is developing novel small molecule GDNF mimetics with the potential for disease-modifying treatments for nervous system disorders
Pre-clinical Trials IND Phase Clinical Trials finalized in 2024 2024-2025 2025+
Paavo Pilv, EMBA, CEO of GeneCode, JMC member of Kevad Bio
Yves Ribeill, PhD, Partner, Entrepreneur-In-Residence, Co-founder of Argobio Studio, JMC member of Kevad Bio
Delphine Charvin, PhD, Operating Partner at Argobio Studio, JMC member of Kevad Bio
Mélanie Rouillier, MSc, PMP, Scientific Project Manager at Argobio Studio
Serge Mignani, PhD, Consultant in Medicinal Chemistry for Argobio Studio
Prof. Dr. Tarmo Tamm, University of Tartu, lead scientist of GeneCode
Prof. Dr. Mart Saarma, Research Director and Professor at the Institute of Biotechnology, University of Helsinki, Sr Partner of GeneCode, CSO, JMC member of Kevad Bio
Arun Mahato, PhD, Institute of Biotechnology, University of Helsinki, lead scientist of GeneCode
Co re
T ea
m Dr. Mehis Pilv, The Company Founder
Discovery Lead Op Preclinical IND Ph I Ph II Ph III
KB-001 (GFRɑ1-RET)
Neuro-protection and restoration in PD
KB-xxx (GFRɑ1-RET)
3 new indications: ALS, RP, IBD
Other
Weight loss
Addiction diseases
Timeline Building a Valuable Pipeline
Today Ahead of Series A
20
Market analyses Building a Valuable Pipeline
21
Indication Patients Compound annual growth rate (CAGR)
Market value Future market value
PD Over 10 million worldwide
14,5% Global market value 2022 $3.4 billion
$7,1 billion by 2029
ALS 4-6 cases per 100,000 individuals
13,9% $282 million in 2019 within the 8 MM
Exceed $1.04 billion by 2029
RP Affects approximately 1 in every 3,000
7,3% Global market value 2021 $11.57 billion
$20.33 billion by 2029
IBD 6-8 million individuals worldwide
5,7% Global market value 2022 $25.18 billion
$37 billion by 2029
ARE WE TALKING ABOUT A POTENTIAL NEW UNICORN?
200
400
600
800
1 000
1 200
Discovery Preclinical Phase 1 Phase 2 Phase 3
Upfront payment Milestone payment Total deal value
Parkinson's Disease - Deal Comparables: Segmented by Stage
of Development
Existing drugs are generic and have very similar treatment
paths. The GeneCode drug is the first one that restores the
neurons affected by PD.
The strategy is to secure a strategic corporate partnership with an
industry-leading pharmaceutical company. The core takeaway
from the deal/transaction comparable analysis shown here is that
there are multiple key time points where GeneCode can expect
to secure a corporate partnership (i.e., preclinical, Phase 1, 2,
3).
$M
The main drive behind these very lucrative financial deals is innovative PD drug treatments offering ‘disease-modifying’ abilities. GeneCode is developing novel PD therapies that also have this important attribute of disease-modifying potential.
Contact
Paavo Pilv CEO
E-mail: [email protected] Mobile: +372 50 20 111GENECODE
Paavo Pilv CEO
E-mail: [email protected] Mobile: +372 50 20 111 [email protected] [email protected]
WORLD TRADE CENTRE®
TALLINN
WTC Tallinn Ltd planned renovation
WTC TALLINN is located in the city centre, between the Old Town, the airport and the port, which serves 12-13 million passengers per year.
WTC Tallinn is the largest privately owned and privately operated office spaces offering company in the Nordic-Baltic region.
WTC Tallinn recently celebrated its 30th year of successful operations.
Starting date of the WTC Tallinn Development Pro- ject is known very precicely - 15th of April 1994. That day formed for that pur- pose and leaded by Dr. Mehis Pilv In- vestment Company RET Development Group LTD bought on the public auc- tion the pancropthed Tallinn Radielectron- ic Plant (RET) big Industrial Quarter in the Tallinn City Centre.
Taking care of the highly attractive location in the Tallinn City Centre, his buildings, proper- ties and the infrastructure, this big Industrial Quarter was decided to convert to the big In- ternational Business Quarter and to apply for it the brand name “World Trade Center Tallinn“. One of the most prominent Estonian Architects Mr. Raine Karp made the shown here the first arhitectual version of this planned to be devel- oped Tallinn Big International Business Quarter and the Application Documents for getting the Tallinn World Trade Center brand name were sent to the World Trade Centers Association (WTCA) HQ in New York.
The RET Development Group WTC Tallinn Brand name Application was in WTCA HQ well accepted and the prepearing of the cor- responding WTCA Membership decicion documentation was delecated to the Chair- man of the Industrializing Nations Committee of the WTCA, Mr. K.H. Wu of WTC Taipei. In connection of defining the various local, related to the Applicant questions, Tallinn was visited by the appointed by the WTCA repre- sentatives - many times by the Regional Coor-
dinator for Central and Eastern Europe of the Industrializ- ing Nations Com- mittee of the WTCA Mr. Guenter Ehring, Director of the WTC RUHR VALLEY.
With prepearing the WTC Tallinn WTCA Membership deci- sion worked also Mr. Matthew Kleink-
necht from the WTCA HQ and among others also Vice President and Secretary General of the WTCA Mr. Tom Kearney. The WTC Tallinn WTCA Membership Application was Supported by the WTCA Board Meetings, by 1995 WTCA Spring Meeting in Mexico and WTCA General Assembly in Beijing and the WTC Trade mark was granted to the WTC Tallinn on April 24, 1995.
Ambitious and innovative use by companys management the various competive advan- tages of this Big Private Tallinn WTC Quarter had made the WTC Tallinn Project from the very beginning selfsufficient and ecomically very profitable during all of the more then 30 years of its succesful operations.
Starting in 2025 the new full Reconstruction of the WTC Tallinn Business Quarter can also be characterized by using of many very ambitious and innovative newest technologies, from outstanding and flexible modern architectual solutions to the AI controlled best possible in- door climate for users. The buildings with best possible energy performance are engineered to be zero emission buildings (ZEB) and they will harvest renewable heating and cooling energy with geothermal heat pump with effec- tive thermal storage in the ground.
Forming of THE WTC TALLINN LTD in 15.04.1994
2
Crucial for occupants comfort air condition-
ing and ventilation systems are silent oper- ation, low velocities and high level of ther- mal comfort and Indoor Air Quality (IAQ ), for that will be used a low-pressure ventilation ductwork of combined air conditioning and heat recovery demand-controlled ventilation system.
Very important are also many unic flexible architectual-constructoral technological solu- tions, which will be also described in more.
DETAILS
All those newest ambitious arhitectural - constructoral - technological solutions with using newest high efficiency AI software will be described more precicely in the next parts of this manual. Also is very important to un- derline, that thanks to very high efficiency of the technological solutions of many WTC Tal- linn Quarter infrastructure systems, some ser- vices can be additionally to the clients of the own WTC Quarter be very profitable deliv- ered also to the neighboring properties - for example central heat and cooling, electrical energy, parking places, connections to public transport et cetera.Tallinn International Electronics
and Trade Center
Architect Raine Karp sketch project from 1994
Borders the harbor area
3
DR. MEHIS PILV has a Ph.D. in Applied Computer Sciences, more than 20 publications on radio-electronics, applied cybernetics and international entrepreneur- ship and more than 10 inventions and patents.
Dr. Pilv is the founder of WTC Tallinn Ltd. He is also the founder GENE- CODE and is a significant investor and business developer.
He is a private owner of the World Trade Center, Tallinn and also has inter- ests in many significant real estate projects.
https://genecode.com/team/mehis-pilv/
The renewable geothermal energy from the WTC Tallinn territory is provided by MAAKÜTE LTD (Geothermal heat energy).
The construction of the WTC Tallinn quarter is being provided by Estonia’s leading construction company MERKO.
WTC Tallinn development team
WTC Tallinn’s ambitious reconstruction project is ensured by the use of top professionals from various fields.
PROF. DR. ANDRES ALVER has taught at the Estonian Academy of Arts (formerly ERKI) since 1985. Since 2006, he has been a full professor. He has worked as a visiting pro- fessor at the College of Architecture of the Virginia Polytechnic Institute (Alexandria, VA) and at the Faculty of Architecture of the private university RISEBA in Riga, and has been a visiting critic at the Department of Archi- tecture of Umea University (Sweden) and the School of Design of Harvard University (Cambridge, MA). www.ata.ee
The globally ambitious architectural solution has been developed by Professor Andres Alver, who is the developer of the architectural solu- tions for many of the new developments in Tallinn. Such as the Roter- mann Center, Krulli Quarter, Smuuli tee Quarter, and so on.
4
PROF. DR. JAREK KURNITSKI is Professor at Tallinn University of Technology, Estonia, and at Aalto Uni- versity, Finland. He is internationally renowned for preparation of techni- cal definitions for nearly zero energy buildings through many activities in REHVA and European standardisation. www.etis.ee/CV/Jarek_Kurnitski/
The ambitious architecture is complemented by one of Estonia’s leading design offices, Disainikorp, with its innovative design solutions.
MA. KAREL KORP Karel Korp is an Estonian designer, illustrator, book designer and painter.
Graduated from Tallinn University with a degree in art education and drawing. In 1997, he founded the advertising and design agency Disaini- korp, which is one of the oldest operating design agencies in Estonia.
He has collaborated with the Bank of Estonia, the Financial Supervision Authority, the Chancellor of Justice, the Employers’ Confederation, the Chamber of Commerce and Industry, the Estonian Cooperation Council, the World Trade Center Tallinn and many other institutions and compa- nies. He has created trademarks and corporate graphics for international- ly operating companies.
He has participated in dozens of exhibitions with his illustrations and paintings both in Estonia and elsewhere in the world.
From 2016 to the present, he has been the chairman of the Estonian Graphic Designers’ Association and one of the owners of the illustration gallery TINT.
www.disainikorp.ee
The most important innovative solution for the reconstructed WTC is to power the new quarter with 100% renewable energy all year round.
The corresponding direction has been developed by Professor Jarek Kurnitski of Tallinn University of Technology and Professor Robert Kitt, Head of Utilitas.
5
Zero Emission Building and optimal Indoor Environmental
Quality targets in
WTC Tallinn In addition to the striking and unique
architectural design, the building’s CO2 footprint and its unique solution based on 100% renewable
geothermal and solar energy should also be noted.
This is described in more detail on the following page.
6
Certified to the highest level of LEED/ BREEAM/WELL should not only demonstrate modern architecture but also to offer best possible indoor climate for users. An opti- mal Indoor Environmental Quality (IEQ ) is of- ten overlooked in value engineering, but it deserves efforts for better user satisfaction, wellbeing and productivity. In WTCT this goes hand in hand with best possible energy per- formance as these buildings aim to be zero emission buildings (ZEB) and beyond before an official definition of ZEB even exists. There are the following three innovative elements to achieve ZEB and optimal IEQ targets in WTCT.
1.
WTCT buildings located in city centre will harvest renewable energy with semi deep boreholes and photovoltaic on-site electric- ity generation. Because of limited size of the building site a common borehole in Estonian soil conditions of 50 m will be replaced with much deeper one. Ongoing experimental drill- ing aims to reach about 600 m with three test boreholes which then will enable to conduct a thermal response test to provide design data for the entire borehole field. It is expected that boreholes with a geothermal heat pump will supply most of the heating and cooling of buildings and enable effective thermal storage in the ground. The rest of heating and cooling energy will be covered with effective district heating and cooling.
2.
To reduce heating and cooling loads, highly performing façade would be needed. As lo- cated in cold climate, facades with four pane glazing units are studied instead of common
triple glazing. Four pane windows with clear low-emission glazing offer superior thermal in- sulation and solar protection at the same time while visible light transmittance can reach 60% that is well enough for facades having high window to wall ratios because of sea views and other architectural reasons. The drawback of four panel glazing are higher weight and a challenge for profile systems to have a space for more than 70 mm thick glazing units. De- pending on energy prices such solution can be cost effective in the long run and WTCT wants to be a forerunner focusing to life cycle cost instead of investment cost.
3.
Air conditioning and ventilation systems are crucial for occupant’s comfort. WTCT pre- fers silent operation, low velocities and sys- tems operating on demand to provide high level of thermal comfort and Indoor Air Qual- ity (IAQ ). A low-pressure ventilation ductwork of combined air conditioning and heat recov- ery demand-controlled ventilation system will be used. This system sized for terminal unit pressure drop has lower velocities and static pressure in the ductwork than usually making it flexible and robust for demand control op- eration even with simple on-off type of damp- ers. WTCT aims to design one of the first air conditioning and ventilation systems in Esto- nia having IAQ regulation and monitoring that is one important feature of future ZEBs. Such design makes IEQ visible for users and bene- fits from utilising passive features but will take more space because of larger ducts. However, careful architectural design and high ceilings in WTCT turn this to be a reasonable solution maximising both energy and IEQ performance.
WTC Tallinn Business Quarter with Zero Emission and optimal Indoor Environment office and living buildings
7
Parda T1 (internal street) 2024 m2
In the quarter, which has a total of 20,000 m2 of plot area and 100,000 m2 of building area, all buildings are accessible by car from various directions.
The street is also wide enough to allow access to the first- floor commercial buildings by commercial vehicle.
Public transport options are located in the immediate vicin- ity of the quarter, which directly connect the port and the airport.
8
NARVA ROAD
Ahtri 8 Ahtri 12
Parda 9
Parda 5
Parda 4 Jõe 3
Jõe 5
Narva 11
Jõe 5A apartment building
Jõe 7 apartment building
Jõe 9
Parda 8
Parda 10
Parda 12
Parda 6
Parda T1 (internal street) 2 024 m2 • 100% WTC
AHTRI STREET
Narva 9
JÕ E STR
EET
◀ ROTERMANN QUARTER
REIDI ROAD ▶
Parda 7
Parda 3
◀ PORTO FRANCO
Parda T1 (internal street) 2024 m2
9
Parda T1 (internal street)
10
11
12
13
Tallinn’s passenger port is around ½ a kilometer away, the city’s main rail- way station is around 3 kilometers away, and Tallinn Airport is around 4 kilometers away.
WTC Tallinn quarter
WTC Tallinn quarter compared to the neighboring Rotermann business district
14
Rotermann quarter
View from Tallinn Town Hall SquareTown Hall Square in the Old Town is around 2 kilometers away.
Starting from this summer, you will be able to take the tram from the harbour directly to the main entrance of the WTC.
15
Parda 9, Ahtri 8/12, Jõe 9 towers reconstructed buildings Upper floor general plan. Gross floor area 3307 m2
View of the projecting part of the apartment
16
132.3 m2
118.4 m2
17
Parda 9, Ahtri 8/12, Jõe 9 towers reconstructed buildings Upper floor general plan. Gross floor area 3307 m2
View of the projecting part of the apartment
18
88.9 m2
82.3 m2
Apartments on the upper floors of Ahtri 8-12
19
1:1 tenant on the floor 2:3 tenant on the floor
931 m2
209 m2 99 m2
107 m2
167 m2
Parda street 3, 5, 7 towers According to the detailed plan, the construction of both offices and living spaces is secured.
20
The three towers above at Parda 3, 5 and 7 are multifunctional buildings with plan- ning permits for both office and residen- tial space. A sufficient number of parking spaces has been provided for both. The towers are planned to be 11-storey build- ings with a height of 38.5 m.
The three described office buildings are designed to conform to the class A stand- ard, which means zero-energy buildings in terms of energy consumption. The lo- cation of the office buildings in the WTC Tallinn quarter provides a significant com- petitive edge.
Technical data of the Parda street 3, 5, 7 three properties:
• Area available for construction: 2 294m2
• No. of floors: 11 • Gross area: 19 077m2
• Net area: 17 309m2
• Parking spaces: 222
21
22
WTC Tallinn Ltd Ahtri 8, 10151 Tallinn, Estonia Phone: +372 626 1001 E-mail: [email protected] • www.wtc.ee
Collaboration and investment proposals: Mehis Pilv, member of the board of WTC Tallinn Phone: +372 50 31 801 E-mail: [email protected] [email protected]
The figure below shows a multifunctional building extending onto the pedestrianised Ahtri Street, the main part of which is an ex- clusive projecting section resting on a braid- ed pipe. Here, too, there will be both office and residential spaces with sufficient parking.
The building was designed to be an energy efficiency class A structure, i.e. a nearly zero energy building with the best available ener- gy efficiency and renewable energy technol- ogy.
23
Area of buildings owned by WTC Quarter
68 313 m2
Area of the properties owned by WTC 12 775 m2
Area of buildings operated by WTC Quarter
30 965 m2
Area of the properties operated by WTC 6 568 m2
Area of the buildings in the quarter
TOTAL: 99 278 m2 or approx. 1 million square feet
Total area of the properties 19 343 m2
NARVA ROAD One of Tallinn’s busiest roads
Ahtri 8 Ahtri 12
Ahtri 8/12 - 23 810 m2 (Current enclosed net area 11 432 m2, according to the zoning plan 23 810 m2, WTC part 93.43%)
Parda 9
Pa rd
a 3,
5 , 7
Parda 4 Jõe 3
Jõe 5
Narva 11
Jõe 5A apartment building
Jõe 7 apartment building
Jõe 9
Parda 8
Parda 10
Parda 12
Parda 6
Jõe 9 - 2 925 m2
100% WTC
Parda 4 3 745 m2
100% WTC
Parda 3, 5, 7 19 020 m2
100% WTC Current enclosed net area 2 617 m2, according to the zoning plan 19 020 m2
Parda 9 - 14 950 m2
Current enclosed net area 9 960 m2, according to the zoning plan 14 950 m2
Parda T1 (internal street) 2 024 m2 • 100% WTC
AHTRI STR.
Narva 9
Additional access to the WTC Quarter
JÕ E STR
.
Additional connection to the WTC Quarter
Building managed by WTC
Property area 2 172 m2
Parda 7 property area 908 m2
Parda 5 property area 1 037 m2
Parda 3 property area 931 m2
Property area 2 977 m2
Property area 710 m2
Property area 740 m2
Property area
295 m2
Property area
240 m2
Property area
905 m2
Current enclosed net area 2 831 m2
Property area
539 m2
Current enclosed net area 1 946 m2
Property area
1 276 m2
Current enclosed net area 3863 m2
Property area 1 406 m2
Current enclosed net area 8 633 m2
Property area 543 m2
Current enclosed net area 4 050 m2
Property area
1 739 m2
Current enclosed net area 7 869 m2ROTERMANN
QUARTER
REIDI ROAD
Current enclosed net area 720 m2
Current enclosed net area 1 999 m2
Property area 901 m2
Current enclosed net area 881 m2
PORTO FRANCO
THE TALLINN WTC QUARTER designed by Professor Andres Alver according to the zoning plan from 2010, with updates starting from 2025
DELFI QUARTER
Parda T1 (internal street)
2 024 m2 • 100% WTC